This is a summary of the European public assessment report (EPAR) for Odomzo. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Odomzo. For practical information about using Odomzo, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not amenable to curative surgery or radiation therapy.
Therapeutic Area (MeSH)
ATC Code
L01XJ02
ATC Item
sonidegib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| sonidegib diphosphate | N/A | Sonidegib |
EMA Name
Odomzo
Medicine Name
Odomzo
Aliases
N/ANo risk management plan link.
